SkinBioTherapeutics (LON:SBTX) Stock Price Down 10.3% – Time to Sell?

SkinBioTherapeutics plc (LON:SBTX) traded down 10.3% during mid-day trading on Tuesday . The stock traded as low as GBX 18.83 and last traded at GBX 18.83. 949,555 shares were traded during mid-day trading, a decline of 34% from the average session volume of 1,447,515 shares. The stock had previously closed at GBX 21.

SkinBioTherapeutics Stock Performance

The firm has a market capitalization of £50.67 million, a price-to-earnings ratio of -63.16 and a beta of 2.01. The firm’s 50 day simple moving average is GBX 15.81 and its 200 day simple moving average is GBX 15.71. The company has a debt-to-equity ratio of 27.57, a quick ratio of 10.01 and a current ratio of 0.93.

SkinBioTherapeutics (LON:SBTX) last announced its quarterly earnings results on Monday, December 8th. The company reported GBX (0.31) earnings per share for the quarter. SkinBioTherapeutics had a negative return on equity of 115.86% and a negative net margin of 237.95%.

SkinBioTherapeutics Company Profile

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.